Anastrozolum 1 - Magnum Laboratories

Unlike older treatments, anastrozole introduced a non-steroidal approach to estrogen suppression when it debuted in 1995. Created by Zeneca, it belonged to a newer class of selective aromatase inhibitors designed to avoid the side effects of steroidal compounds. This distinction allowed for better patient tolerance and fewer complications associated with long-term therapy. Its role was reinforced by the extensive ATAC clinical study, which compared it head-to-head with tamoxifen and helped redefine hormonal therapy in postmenopausal oncology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrozolum 1 by Magnum Laboratories, consult with your doctor or healthcare professional.